ARGX vs QGEN
argenx SE vs Qiagen N.V. — AI-powered side-by-side comparison
| Metric | ARGX | QGEN |
|---|
| AI Score |
69
|
64
|
| Price |
$864.40
|
$42.66
|
| P/E Ratio |
31.34×
|
21.87×
|
| ROE |
17.6%
|
11.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
61.7%
|
| Debt / Equity |
0.01×
|
0.49×
|
| Dividend Yield |
0.0%
|
6.2%
|
| RSI (14) |
47.9
|
57.5
|
| Beta |
-0.022
|
0.62
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus QGEN.
ARGX leads by 5 points.
ARGX scores 69/100 (Buy) versus QGEN at 64/100 (Buy).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
QGEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- EPS growing 341.4% YoY — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro